A Multi-center, Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination With Optimized Background Therapy in Treatment-Experienced HIV-1 Subjects
Phase of Trial: Phase II/III
Latest Information Update: 20 Nov 2016
At a glance
- Drugs PRO 140 (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Registrational; Therapeutic Use
- Sponsors CytoDyn
- 07 Jun 2017 Biomarkers information updated
- 05 Oct 2016 Planned number of patients changed from 300 to 30.
- 05 Oct 2016 Status changed from active, no longer recruiting to recruiting.